
Following hours of discussion over safety concerns, a U.S. Food and Drug Administration advisory panel on Wednesday recommended approval of a second RSV vaccine, this one made by GlaxoSmithKline, for use in Americans ages 60 and older. The panel’s recommendation was based largely on the results of a trial that tested the GlaxoSmithKline vaccine in… read on > read on >